Just an FYI for forum readers:
Senesco technologies is just starting their clinical program with SNS01-T at the Mayo clinic, University of Arkansas and West Virginia University medical centers. Their drug is clearly one to watch moving forward, given that it represents a potential breakthrough in treatment for multiple myeloma.
The first trial is predominantly a trial to show safety, among relapsed and refractory patients.
Their preclinical data has been very impressive, to say the least, and they reported early interim results from their trial yesterday at ASCO. The first patient treated now has stable disease, after receiving just 1/30 of what will be the high dose in this trial -- these are very unexpected results. Two patients had to drop out of the study because their disease was too far progressed before the treatment ended and thus not qualified to participate in the trial. Two more are currently being treated. Look for updates later this summer.
Here is an article about the treatment:
http://njtcblog.files.wordpress.com/2011/03/senescolsmarch.pdf
And here is an interview with the CEO, Les Browne that was published today:
http://www.reuters.com/article/2012/06/05/idUS155208+05-Jun-2012+HUG20120605
I also have an in depth report on the company and the technology if anyone is interested.
Thanks
Forums
4 posts
• Page 1 of 1
Re: SNS01-T
Hello ptbag22,
Thank you for the information.
Feel free to post your report to the forum. You can post attachments if you are a registered user of the forum, and anyone is welcome to register. Use of the forum for commercial purposes, however, is not permitted.
Also, just to clarify for forum readers, no trial results for SNS01-T were presented in either an oral or poster presentation during the ASCO meeting. This is more than a technicality, since anything approved for presentation at the meeting has to go through a peer review process.
Senesco did issue a press release with information about initial results from the ongoing trial that it is sponsoring. The press release is duplicated below in case anyone is interested.
For a list of all Beacon news articles related to SNS01-T, see this link:
https://myelomabeacon.org/tag/sns01-t/
Press Release:
Senesco Provides SNS01-T Update on Phase 1b/2a Multiple Myeloma Trial
BRIDGEWATER, N.J. (June 4th, 2012) – Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) reported today on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology.
To date five patients have been enrolled into the study. So far one patient has completed the 6 week dosing schedule. This patient’s disease was considered stable, no disease progression, based on key disease markers including monoclonal protein when evaluated at the end of weeks 3 and 6. Two patients were withdrawn from the study due to disease progression, and two patients are currently being treated. No disease limiting toxicities have been recorded to date.
“We are encouraged that there is an indication that SNS01-T is performing as designed even at this low dose,” stated Harlan Waksal, M.D., Chairman of Senesco. “At this dose level we had expected to evaluate only safety. So seeing an indication of activity, even in a single patient, is a bonus.”
In the study, patients are dosed twice-weekly for 6 weeks followed by an observation period. The first group of patients receives 0.0125 mg/kg by intravenous infusion. At the end of 6 weeks of dosing, safety data for the group will be reviewed before the subsequent group receives a higher dosage. The escalated doses administered to the second to fourth groups will be 0.05, 0.2 and 0.375 mg/kg, respectively.
“We are pleased that the SNS01-T study is progressing well. Provided there are no more withdrawals we expect to complete the first dosing group during the last week of June,” stated Leslie J. Browne, Ph.D., President and Chief Executive Officer of Senesco. “Although we experienced an initial delay in patient enrollment, we believe that the rate of recruitment into the study is back on plan.”
The study is an open-label, multiple-dose, dose-escalation study, which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to approximately 15 relapsed or refractory multiple myeloma patients. While the primary objective of this study is to evaluate safety and tolerability, the effect of SNS01-T on tumor response and time to relapse or progression will be assessed using multiple well-established metrics including measurement of monoclonal protein.
About SNS01-T
SNS01-T is a novel approach to cancer therapy that is designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma, and, mantle cell and diffuse large B-cell lymphomas. Senesco is the sponsor of the Phase 1b/2a study that is actively enrolling patients at Mayo Clinic in Rochester, MN, the University of Arkansas for Medical Sciences in Little Rock, and the Mary Babb Randolph Cancer Center in Morgantown, WV. http://www.clinicaltrials.gov/ct2/show/NCT01435720
Thank you for the information.
Feel free to post your report to the forum. You can post attachments if you are a registered user of the forum, and anyone is welcome to register. Use of the forum for commercial purposes, however, is not permitted.
Also, just to clarify for forum readers, no trial results for SNS01-T were presented in either an oral or poster presentation during the ASCO meeting. This is more than a technicality, since anything approved for presentation at the meeting has to go through a peer review process.
Senesco did issue a press release with information about initial results from the ongoing trial that it is sponsoring. The press release is duplicated below in case anyone is interested.
For a list of all Beacon news articles related to SNS01-T, see this link:
https://myelomabeacon.org/tag/sns01-t/
Press Release:
Senesco Provides SNS01-T Update on Phase 1b/2a Multiple Myeloma Trial
BRIDGEWATER, N.J. (June 4th, 2012) – Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) reported today on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology.
To date five patients have been enrolled into the study. So far one patient has completed the 6 week dosing schedule. This patient’s disease was considered stable, no disease progression, based on key disease markers including monoclonal protein when evaluated at the end of weeks 3 and 6. Two patients were withdrawn from the study due to disease progression, and two patients are currently being treated. No disease limiting toxicities have been recorded to date.
“We are encouraged that there is an indication that SNS01-T is performing as designed even at this low dose,” stated Harlan Waksal, M.D., Chairman of Senesco. “At this dose level we had expected to evaluate only safety. So seeing an indication of activity, even in a single patient, is a bonus.”
In the study, patients are dosed twice-weekly for 6 weeks followed by an observation period. The first group of patients receives 0.0125 mg/kg by intravenous infusion. At the end of 6 weeks of dosing, safety data for the group will be reviewed before the subsequent group receives a higher dosage. The escalated doses administered to the second to fourth groups will be 0.05, 0.2 and 0.375 mg/kg, respectively.
“We are pleased that the SNS01-T study is progressing well. Provided there are no more withdrawals we expect to complete the first dosing group during the last week of June,” stated Leslie J. Browne, Ph.D., President and Chief Executive Officer of Senesco. “Although we experienced an initial delay in patient enrollment, we believe that the rate of recruitment into the study is back on plan.”
The study is an open-label, multiple-dose, dose-escalation study, which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to approximately 15 relapsed or refractory multiple myeloma patients. While the primary objective of this study is to evaluate safety and tolerability, the effect of SNS01-T on tumor response and time to relapse or progression will be assessed using multiple well-established metrics including measurement of monoclonal protein.
About SNS01-T
SNS01-T is a novel approach to cancer therapy that is designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma, and, mantle cell and diffuse large B-cell lymphomas. Senesco is the sponsor of the Phase 1b/2a study that is actively enrolling patients at Mayo Clinic in Rochester, MN, the University of Arkansas for Medical Sciences in Little Rock, and the Mary Babb Randolph Cancer Center in Morgantown, WV. http://www.clinicaltrials.gov/ct2/show/NCT01435720
Re: SNS01-T
I mentioned in a comments on one of the Beacon's recent articles that readers should interpret with caution any comments or forum postings they see here about SNS01-T.
I said: "the stock of the company that is developing SNS-01T is essentially a penny stock, so there are all sorts of people pumping SNS01T as “the next best thing” just so they can make a buck or two on swings in the stock’s price."
Just to drive that point home, let me point people to this recent posting -- http://tinyurl.com/cxn8sjk -- on the message board over at Yahoo Finance for Senesco, the company developing SNS01-T.
A Senesco investor writing on the Yahoo Finance message board said earlier today: "I posted the early findings [about SNS01-T] on the Myeloma Beacon message board, as to raise some awareness among patients."
I'm not saying what has been posted here about SNS01-T is wrong. But there's a definite spin to what was posted that is more understandable now that we know the source of the posting.
This is probably going to happen more often, so just beware and be critical of what you read.
I said: "the stock of the company that is developing SNS-01T is essentially a penny stock, so there are all sorts of people pumping SNS01T as “the next best thing” just so they can make a buck or two on swings in the stock’s price."
Just to drive that point home, let me point people to this recent posting -- http://tinyurl.com/cxn8sjk -- on the message board over at Yahoo Finance for Senesco, the company developing SNS01-T.
A Senesco investor writing on the Yahoo Finance message board said earlier today: "I posted the early findings [about SNS01-T] on the Myeloma Beacon message board, as to raise some awareness among patients."
I'm not saying what has been posted here about SNS01-T is wrong. But there's a definite spin to what was posted that is more understandable now that we know the source of the posting.
This is probably going to happen more often, so just beware and be critical of what you read.
-
TerryH
Re: SNS01-T
Terry -- I understand your cautionary message to the Forum readers, and agree fully that all postings should be taken with a grain of salt and maybe even some healthy skepticism, but that being said, if you take the time to research the company and the technology, I think you might agree that this is information that truly belongs on this forum.
I have been following this company for years, only very recently as an investor. This company's financial situation has been compromised by poor management, not suspect technology, but two years ago Harlan Waksal, the former co-founder of Imclone, came in and saved this company. SNS01-T has only been administered to 5 patients, so there clearly is no evidence yet to suggest it is safe, well tolerated, or effective, however it represents a promising new technology, that all patients deserve to be aware of.
Only 1 patient has completed the treatment, and has been classified as having stable disease. This was surprising because the dose they received was only 1/30 of what will be the highest dose in this trial. More updates will be announced in the coming months. If this interests patients and their families they can learn more about the trial here:
http://www.clinicaltrials.gov/ct2/show/NCT01435720
Let me make a few points:
1. The technology they have was originally only applied in agricultural applications. They currently have field trials in progress with many of the big names in agri-science in most of the major crops. Through up-regulating factor 5A (the pro survival form of the protein) they have shown the ability to grow plants in highly stressed environments, including growing bananas that are resistant to the Black Sigatoka fungal virus, which currently threatens the world's Cavendish banana crop. They have also shown the ability to grow poplar trees twice as quickly as normal without any reduction in the quality of the wood.
2. Factor 5A has a prominent role in all eukaryotic cells (all plants and animals) and their pre-clinical work has shown to be highly effective in killing every type of cancer cell they have tested. One reason the company chose multiple myeloma as their initial indication was because it is a disease that badly needs treatments that are effective in refractory/relapsed patients. Also, therapies that have vastly reduced side effects are also in great demand. The company believes that in this drug they potentially have both.
3. Their preclinical work in animals has been described by Dr. Les Browne as more impressive than the currently available multiple myeloma treatments. Very high rates of tumor eradication as a monotherapy, and in combination with Revlimid high rates of complete tumor eradication. Revlimid alone produced inferior results to both SNS01-T alone and the SNS/Revlimid combination.
I have been following this company for years, only very recently as an investor. This company's financial situation has been compromised by poor management, not suspect technology, but two years ago Harlan Waksal, the former co-founder of Imclone, came in and saved this company. SNS01-T has only been administered to 5 patients, so there clearly is no evidence yet to suggest it is safe, well tolerated, or effective, however it represents a promising new technology, that all patients deserve to be aware of.
Only 1 patient has completed the treatment, and has been classified as having stable disease. This was surprising because the dose they received was only 1/30 of what will be the highest dose in this trial. More updates will be announced in the coming months. If this interests patients and their families they can learn more about the trial here:
http://www.clinicaltrials.gov/ct2/show/NCT01435720
Let me make a few points:
1. The technology they have was originally only applied in agricultural applications. They currently have field trials in progress with many of the big names in agri-science in most of the major crops. Through up-regulating factor 5A (the pro survival form of the protein) they have shown the ability to grow plants in highly stressed environments, including growing bananas that are resistant to the Black Sigatoka fungal virus, which currently threatens the world's Cavendish banana crop. They have also shown the ability to grow poplar trees twice as quickly as normal without any reduction in the quality of the wood.
2. Factor 5A has a prominent role in all eukaryotic cells (all plants and animals) and their pre-clinical work has shown to be highly effective in killing every type of cancer cell they have tested. One reason the company chose multiple myeloma as their initial indication was because it is a disease that badly needs treatments that are effective in refractory/relapsed patients. Also, therapies that have vastly reduced side effects are also in great demand. The company believes that in this drug they potentially have both.
3. Their preclinical work in animals has been described by Dr. Les Browne as more impressive than the currently available multiple myeloma treatments. Very high rates of tumor eradication as a monotherapy, and in combination with Revlimid high rates of complete tumor eradication. Revlimid alone produced inferior results to both SNS01-T alone and the SNS/Revlimid combination.
-
ptbag22
4 posts
• Page 1 of 1
Return to Treatments & Side Effects